lm103
Solid Cancer
Suzhou BlueHorse Therapeutics Co., Ltd.Early Phase 1Active
C
36/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 73/ 100
Competitive context
30 Active assets in the Solid Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Beijing GoBroad Hospital | Phase 1/2 | CCC |
Regorafenib Bayer | Phase 2 | CCC |
Hycamtin Daiichi Sankyo | Phase 2/3 | CCC |
immunoglobulin G1-kappa, anti-[Homo sapiens CDH6(cadherin 6, K-cadherin (foetal kidney), cadherin 6 type 2)], humanized monoclonal antibody conjugated to deruxtecan, comprising a linker and a camptothecin derivative Daiichi Sankyo | Phase 2/3 | CCC |
Inno-206 Daiichi Sankyo | Phase 2/3 | CCC |
View all 35 →
Same molecule, other indications
lm103 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →